CN118284417A - Nurr1激动剂与醛固酮拮抗剂、胰岛素调节剂和磺酰脲中的至少一种的组合 - Google Patents

Nurr1激动剂与醛固酮拮抗剂、胰岛素调节剂和磺酰脲中的至少一种的组合 Download PDF

Info

Publication number
CN118284417A
CN118284417A CN202280071517.2A CN202280071517A CN118284417A CN 118284417 A CN118284417 A CN 118284417A CN 202280071517 A CN202280071517 A CN 202280071517A CN 118284417 A CN118284417 A CN 118284417A
Authority
CN
China
Prior art keywords
pharmaceutically acceptable
acceptable salt
amodiaquine
structural
combination
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202280071517.2A
Other languages
English (en)
Chinese (zh)
Inventor
乔治·沃吉特兹斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genesis Pharma Sa
Original Assignee
Genesis Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genesis Pharma Sa filed Critical Genesis Pharma Sa
Publication of CN118284417A publication Critical patent/CN118284417A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/569—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone substituted in position 17 alpha, e.g. ethisterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Zoology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN202280071517.2A 2021-08-27 2022-08-26 Nurr1激动剂与醛固酮拮抗剂、胰岛素调节剂和磺酰脲中的至少一种的组合 Pending CN118284417A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GR20210100572 2021-08-27
GR20210100572 2021-08-27
PCT/IB2022/058008 WO2023026247A1 (en) 2021-08-27 2022-08-26 Combination of a nurr1 agonist with at least one of an aldosterone antagonist, an insulin modulator and a sulfonylurea

Publications (1)

Publication Number Publication Date
CN118284417A true CN118284417A (zh) 2024-07-02

Family

ID=83598699

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202280071517.2A Pending CN118284417A (zh) 2021-08-27 2022-08-26 Nurr1激动剂与醛固酮拮抗剂、胰岛素调节剂和磺酰脲中的至少一种的组合

Country Status (5)

Country Link
US (1) US20240366729A1 (https=)
EP (1) EP4392033A1 (https=)
JP (1) JP2024534156A (https=)
CN (1) CN118284417A (https=)
WO (1) WO2023026247A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220265776A1 (en) * 2019-07-09 2022-08-25 Genesis Pharma Sa Combination

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140256626A1 (en) 2011-10-18 2014-09-11 Prolynx Llc Peg conjugates of exenatide
ES2791301T3 (es) * 2015-11-06 2020-11-03 Genesis Pharma Sa Combinación de canrenoato y exenatida
EP3498279A4 (en) * 2016-08-12 2020-04-29 Novmetapharma Co., Ltd. PHARMACEUTICAL COMPOSITION WITH AMODIAQUIN AND ANTIDIABETIC MEDICINAL PRODUCT AS AN ACTIVE SUBSTANCE FOR PREVENTING OR TREATING DIABETES
US20220265776A1 (en) 2019-07-09 2022-08-25 Genesis Pharma Sa Combination

Also Published As

Publication number Publication date
JP2024534156A (ja) 2024-09-18
WO2023026247A1 (en) 2023-03-02
US20240366729A1 (en) 2024-11-07
EP4392033A1 (en) 2024-07-03

Similar Documents

Publication Publication Date Title
US10342797B2 (en) Solubility of therapeutic agents
WO2011028794A2 (en) Treatment of huntington's disease with cycloserine and an nmda receptor antagonist
US20230263854A1 (en) Treatment of Constipation-Predominant Irritable Bowel Syndrome
WO2018053275A1 (en) Use of pridopidine for the treatment of familial dysautonomia
RU2494736C2 (ru) Комбинация, включающая паклитаксел, для лечения рака яичников
JP7758655B2 (ja) 組合せ
CN118284417A (zh) Nurr1激动剂与醛固酮拮抗剂、胰岛素调节剂和磺酰脲中的至少一种的组合
JP6928611B2 (ja) 組合せ
JP7745571B2 (ja) 肺線維症を処置する方法
CN116236491B (zh) 鼠李糖在制备用于治疗或预防神经退行性疾病的药物中的用途、药物组合物及其应用
EP2985037B1 (en) A pharmaceutical composition comprising palmitoylethanolamid and cytidine-diphosphocholine
Parodi et al. Ten-year efficacy and safety of once-daily tacrolimus in kidney transplant: A prospective cohort study
CN110325214A (zh) 用于预防和治疗神经元损伤的低剂量药物组合
JP7569492B2 (ja) 抗精神病薬誘発性体重増加のミリコリラントによる治療方法
TW201806599A (zh) 用於快速開始抗抑鬱作用之給藥方案
AU2002366975B2 (en) Quinazolinone compounds in combined modalities for improved cancer treatment
CN110664799B (zh) 用于治疗脑缺血的药物组合物及其应用
CN118973563A (zh) 5-氨基-2,3-二氢-1,4-酞嗪二酮与富马酸酯的组合
KR20150105496A (ko) 다폭세틴 및 염산클로미프라민으로부터 선택되는 조루치료제 및 pde5 억제제가 분리된 형태로 존재하는 경구투여 약제학적 제형

Legal Events

Date Code Title Description
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination